

BOVen in patients with TN CLL/SLL: Long-term follow-up results (NCT03824483)

N = 52

Primary endpoint: uMRD4. **Eligibility:** Adult patients with TN CLL/SLL; required treatment per 2018 iwCLL guidelines; adequate organ function; adequate hematologic function, unless due to CLL/SLL.

TRIAL DESIGN

